证券代码：688136 证券简称：科兴制药 公告编号：2026-009 科兴生物制药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 （1）经科兴生物制药股份有限公司（以下简称"公司"）财务部门初步测 算，预计 2025 年年度实现归属于母公司所有者的净利润为 13,500 万元至 17,500 万元，与上年同期（法定披露数据）相比，将增加 10,352 万元至 14,352 万元， 同比增加 328.83%至 455.89%。 （2）预计归属于母公司所有者的扣除非经常性损益的净利润为 5,000 万元 至 7,000 万元，与上年同期（法定披露数据）相比，将增加 1,475 万元至 3,475 万元，同比增加 41.83%至 98.56%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：5,690.26 万元。归属于母公司所有者的净利润：3,148.09 万元。归属于母公司所有者的扣除非经常性损益的净 ...

南财智讯1月30日电，科兴制药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 13500万元—17500万元，同比预增328.83%—455.89%；预计2025年全年归属于上市公司股东的扣除非 经常性损益的净利润为5000万元—7000万元，同比预增41.83%—98.56%。本期业绩变化的主要原因： 2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收入持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。报告期内非经常性 损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子公司所致。 ...

科兴制药公告，预计2025年年度实现归属于母公司所有者的净利润为1.35亿元至1.75亿元，同比增加 328.83%至455.89%。预计归属于母公司所有者的扣除非经常性损益的净利润为5000万元至7000万元， 同比增加41.83%至98.56%。上年同期，归属于母公司所有者的净利润为3148.09万元，归属于母公司所 有者的扣除非经常性损益的净利润为3525.43万元。本期业绩变化的主要原因为公司积极开拓海外市 场，实现了海外收入的强劲增长，推动公司营业收入持续增长。 ...

Group 1: Strategic Development Initiatives - Jinan's Zhangqiu District aims to transform strategic deployments into practical actions, focusing on project construction as a core approach to achieve new breakthroughs [2] - The district plans to implement upgrades for heavy-duty truck group’s new energy vehicle models and establish a shared pilot workshop and logistics center to enhance its manufacturing capabilities [2] - The "Gongfu Zhangqiu" initiative will facilitate the digital transformation of over 30 enterprises this year, while also deepening the aerospace information industry chain and focusing on key technologies like rocket component processing [2] Group 2: Project Empowerment and Industrial Growth - The district will prioritize project development, aiming to have at least 500 projects in the pipeline and implement no less than 120 industrial projects throughout the year [3] - Targeted industrial chain investment will lead to the signing of at least 80 new projects this year [3] Group 3: Tourism and Cultural Development - The ongoing construction of the 4A-level scenic area in Bu Village aims to boost the ice and snow economy, creating a sports paradise for skiing enthusiasts [4] - The "Datang Baiquan Yi" project is expected to open this year, serving as a significant driver for service industry development in Zhangqiu District [4] - Efforts will be made to enhance the "Longshan Spring Culture and Tourism City" brand by revitalizing cultural resources and promoting the integration of modern service industries with advanced manufacturing and agriculture [4] Group 4: Education and Innovation Collaboration - Zhangqiu District will leverage its rich educational resources to foster collaboration between universities and local industries, aiming to align academic research with regional industrial needs [5] - The district plans to advance the construction of Shandong University’s Longshan campus and deepen the integration of education and industry in the aerospace information sector [5] - Initiatives will include the establishment of innovation parks and support for the formation of innovation alliances between enterprises and academic institutions [5] Group 5: Infrastructure and Logistics Development - The district will enhance regional industrial collaboration and improve logistics capabilities, focusing on advanced manufacturing and new energy equipment [6] - Infrastructure improvements will be made to facilitate the flow of resources, including the development of the Xiaoqing River Zhangqiu Port logistics park [6] - The district aims to integrate urban and rural development, promoting smart agriculture and creating provincial-level smart agriculture application bases [6]

Group 1: Strategic Development Goals - The year 2026 marks the beginning of the "14th Five-Year Plan" and is a critical point for the transformation of Zhangqiu District, which aims to become a hub for technological innovation and modern urban development [1] - Zhangqiu District has been assigned four key functional roles: a high ground for technological innovation, a cultural tourism city, a demonstration area for school-local collaboration, and a modernized strong district within the Jinan metropolitan area [1] Group 2: Industrial Development Initiatives - The automotive industry is a primary focus, with plans to advance the production of new energy vehicles and core components, including upgrades to the heavy truck group's new energy models [3] - The district aims to complete the digital transformation of over 30 enterprises this year and enhance the aerospace information industry chain, particularly in rocket component processing [5] Group 3: Tourism and Cultural Development - The district plans to enhance its tourism sector through projects like the 4A-level scenic area in Bucun and the Datang Baiquan Inn, which will focus on the "ice and snow economy" [6][8] - The Datang Baiquan Inn aims to create an immersive experience reflecting the Tang Dynasty lifestyle, contributing to the service industry's growth in Zhangqiu [8] Group 4: Educational and Research Collaboration - Zhangqiu District is leveraging its rich educational resources by promoting collaboration between universities and local industries, aiming to align academic research with industrial needs [9] - Plans include the establishment of innovation alliances between enterprises and educational institutions, as well as the construction of a collaborative innovation park [11] Group 5: Infrastructure and Logistics Development - The district is focused on enhancing regional industrial collaboration and improving logistics capabilities, including the construction of the Xiaoqing River Zhangqiu Port logistics park [12][14] - Infrastructure improvements will facilitate better connectivity and support the integration of modern agriculture with urban markets [14]

随着全国多地进入流感高发期，公众健康防护再次成为社会焦点。国家卫健委监测数据显示，流感活动水平持续攀升，尤其在儿童及青少年群体中检出 率更高，凸显了科学防治的紧迫性[1]。在这一背景下，早期、有效的抗病毒干预对于缩短病程、降低重症风险、遏制病毒传播同样至关重要。作为深耕 抗病毒领域多年的生物制药企业，科兴制药（688136.SH）始终以创新为驱动，为呼吸道病毒感染防治提供更多样、更便捷的解决方案。 一、 从"广谱"到"精准"：干扰素的抗病毒防线 流感由流感病毒引起，其快速复制和传播能力是导致疾病流行的关键。理想的抗病毒策略之一是尽早激活并强化人体自身的固有免疫防御。干扰素，正 是人体抵御病毒感染的第一道天然防线。当病毒入侵时，细胞会迅速产生干扰素，它通过激活一系列下游效应蛋白，在细胞间建立"抗病毒状态"，从而 抑制病毒的复制与扩散[2]。 人干扰素α1b是中国自主研发的I型干扰素，具有天然、广谱的抗病毒活性和相对温和的免疫调节特性。科兴制药是国内较早从事干扰素研发与生产的企 业，公司核心产品-注射用人干扰素α1b（商品名：赛若金 ）自上市以来，已在临床广泛应用三十载。 二、 赛若金 ：经典可靠的抗病毒"卫士" ...

Group 1 - The Chinese yuan has started the year strong, with the central bank's midpoint rate against the US dollar reported at 7.0120, an increase of 17 basis points, approaching the 7.0 mark [1] - As of early 2026, the yuan has appreciated by 0.26% against the dollar, while the spot exchange rate has risen approximately 0.2% [1] - Over 20 A-share listed companies, including Whirlpool and Artis, have announced plans to engage in foreign exchange hedging to mitigate market risks [4] Group 2 - Among the companies, three from Shandong province, including Sanyou and Senqilin, have announced foreign exchange hedging plans with total transaction amounts not exceeding 750 million, 6 billion, and 100 million yuan respectively [4] - Senqilin, the largest among these, aims to lock in costs and reduce financial expenses as it expands its international transactions under its "833plus" strategy [5] - The foreign exchange hedging ratio for Shandong enterprises has increased from 16.83% in 2020 to 30.39% by September 2025, indicating a growing trend among companies to use financial tools for risk management [5] Group 3 - China's foreign trade continues to expand, with total import and export volume reaching 45.47 trillion yuan in 2025, a year-on-year increase of 3.8%, maintaining its position as the world's largest goods trading nation [5] - The increasing scale of foreign exchange receipts and payments, coupled with a volatile exchange rate environment, has made foreign exchange hedging a necessary action for many enterprises [5] - The core goal of foreign exchange hedging is to lock in future exchange rates and convert financial uncertainties from exchange rate fluctuations into certainties [6] Group 4 - Experts predict a cautious but optimistic outlook for the yuan in 2026, with expectations of continued appreciation in the first half of the year, but increased uncertainty in the second half due to potential changes in US political and tariff policies [7] - The macro team at Industrial Securities believes that while yuan appreciation is likely to continue, the most aggressive phase may have passed, as the central bank aims to avoid creating expectations of unilateral appreciation [7]

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced fluctuations, with a recent decline of 2.06%, while the company shows a year-to-date increase of 11.34% in stock price, indicating mixed market sentiment towards its performance and potential [1]. Financial Performance - For the period from January to September 2025, Kexing Pharmaceutical achieved a revenue of 1.148 billion yuan, representing a year-on-year growth of 10.54% [2]. - The net profit attributable to shareholders for the same period was 111 million yuan, showing a significant year-on-year increase of 547.70% [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 25.03% to 11,800, while the average circulating shares per person decreased by 19.37% to 17,102 shares [2]. - The stock has seen a net outflow of 8.37 million yuan from major funds, with significant buying and selling activity from large orders [1]. Dividend Distribution - Kexing Pharmaceutical has distributed a total of 51.54 million yuan in dividends since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the second-largest shareholder with 2.0621 million shares, a decrease of 1.6069 million shares from the previous period [3]. - Other significant changes in institutional holdings include an increase in shares held by Fortune Tianhui Growth Mixed A/B and a decrease in shares held by Fortune Precision Medical Flexible Allocation Mixed A [3].

Core Viewpoint - Erythropoietin (EPO) is a glycoprotein hormone crucial for red blood cell production, primarily secreted by the kidneys, with significant implications for treating various types of anemia, particularly in chronic kidney disease (CKD) patients [1][2][4]. Group 1: EPO Drug Overview - EPO is essential for stimulating red blood cell production and regulating oxygen supply in the body, with applications in treating renal anemia, chemotherapy-related anemia, anemia in premature infants, and perioperative red blood cell mobilization [4][5]. - The global prevalence of CKD has significantly increased, with 156 million cases reported in China in 2023, up from 75.42 million in 1990, highlighting the growing public health challenge [6][7]. Group 2: Market Dynamics - The Chinese EPO drug market is projected to decline from 30 billion yuan in 2024 to 31 billion yuan in 2025, before recovering to 37 billion yuan by 2030, with a compound annual growth rate (CAGR) of 3.6% from 2025 to 2030 [7][9]. - Economic factors and healthcare limitations have resulted in unmet needs for renal anemia and other related conditions, suggesting a rising demand for EPO as healthcare access improves [9]. Group 3: Competitive Landscape - The EPO market in China is concentrated, with the top three companies holding 56.1% market share in 2024, led by Sangamo Therapeutics with over 30% market share, followed by Kexing Pharmaceutical at 16.7% [10]. - As of 2025, there are 79 EPO products approved in China, with significant competition among domestic companies, although many remain focused on first-generation EPO products rather than advancing to second-generation long-acting formulations [10].

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]